List of Excipients in Branded Drug VISTOGARD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BTG International Inc	VISTOGARD	uridine triacetate	50633-220	ETHYLCELLULOSE	2027-08-17
BTG International Inc	VISTOGARD	uridine triacetate	50633-220	HYPROMELLOSE	2027-08-17
BTG International Inc	VISTOGARD	uridine triacetate	50633-220	ORANGE JUICE	2027-08-17
BTG International Inc	VISTOGARD	uridine triacetate	50633-220	POLYETHYLENE GLYCOL	2027-08-17
Wellstat Therapeutics Corporation	VISTOGARD	uridine triacetate	69468-151	ETHYLCELLULOSE	2027-08-17

Vistogard Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Vistogard is an oral granule product containing 10 grams of uridine triacetate per packet. Its commercial value depends on rapid administration, dose delivery, stability, and ease of use during fluoropyrimidine toxicity emergencies. The excipient system is relatively simple, which creates opportunities for generic manufacturers, contract development and manufacturing organizations, packaging suppliers, and lifecycle-management developers. The main technical barriers are dose uniformity, powder handling, moisture control, palatability, and regulatory demonstration of pharmaceutical equivalence.

What is Vistogard and how is it administered?

Vistogard is approved by the U.S. Food and Drug Administration for adults and pediatric patients who experience an overdose of 5-fluorouracil or capecitabine, or who develop early-onset, severe or life-threatening toxicity from those drugs. Treatment must begin within 96 hours after the end of fluoropyrimidine administration.[1]

The product is supplied as oral granules in single-use packets.

Attribute	Vistogard information
Active ingredient	Uridine triacetate
Strength	10 grams per packet
Dosage form	Oral granules
Administration	Mixed with soft food or liquid and administered orally
Adult dose	10 grams every six hours for 20 doses
Pediatric dose	6.2 grams per square meter every six hours, up to 10 grams per dose, for 20 doses
Approved use	Emergency treatment of 5-fluorouracil or capecitabine overdose and serious early toxicity
FDA application	NDA 207232
Sponsor	Wellstat Therapeutics Corporation
FDA approval	2015

The dosing schedule requires 20 administrations over five days. The packet format reduces dose-measurement errors and supports hospital, oncology-clinic, and outpatient use.

What excipients are used in Vistogard?

The Vistogard label identifies lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate as inactive ingredients.[1]

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Supports powder volume, flow, and dose handling
Microcrystalline cellulose	Filler and structural aid	Improves granule integrity and content uniformity
Colloidal silicon dioxide	Glidant and anti-caking agent	Improves flow and reduces powder cohesion
Magnesium stearate	Lubricant	Reduces adhesion during manufacturing and filling

The active ingredient represents a high mass fraction of each packet. That limits the amount of excipient available for improving taste, flow, compressibility, or dispersion. The formulation therefore depends on efficient processing rather than a large excipient package.

The label does not identify a specialized polymer coating, lipid delivery system, ion-exchange resin, or extended-release technology. This creates a relatively accessible formulation platform for competitors, but it also increases the importance of manufacturing execution.

How does the excipient system affect Vistogard manufacturing?

Powder flow and packet filling

A 10-gram dose places significant demands on powder flow. Uridine triacetate and lactose-based blends may exhibit segregation, electrostatic charging, or variable bulk density. Colloidal silicon dioxide and controlled granulation can improve flow, but excessive glidant may affect wetting and dispersion.

Manufacturers should control:

• Bulk and tapped density
• Hausner ratio and Carr index
• Particle-size distribution
• Water activity and residual moisture
• Blend uniformity
• Packet weight variation
• Electrostatic behavior during filling

A generic manufacturer that uses a direct-blend process may face greater variability than one using a controlled wet or dry granulation process. The selected process must preserve uridine triacetate stability and avoid chemical interaction with water or processing aids.

Dose uniformity

The product contains a large active dose, which simplifies some content-uniformity concerns compared with low-dose products. The primary risk shifts to packet-to-packet weight accuracy and segregation during handling.

The active ingredient and excipients may differ in particle size and density. This can produce stratification during transfer from the blender to the filling machine. Narrow particle-size specifications and validated hold times are important commercial differentiators for a contract manufacturer.

Moisture and stability

Moisture control is central to the product strategy. Lactose, microcrystalline cellulose, and uridine triacetate can respond differently to humidity. Moisture uptake may affect:

• Powder flow
• Packet fill accuracy
• Granule dispersion
• Chemical stability
• Caking during storage
• Patient experience after opening

Single-dose foil or high-barrier laminate packaging is commercially important. A lower-cost package that increases moisture exposure could create shelf-life or performance problems even if the formulation composition remains pharmaceutically equivalent.

What formulation opportunities exist for Vistogard competitors?

The most practical opportunities involve improving handling and administration without changing the product’s essential dosage form.

Taste masking

Uridine triacetate granules may be difficult for some patients to tolerate because the product is administered repeatedly over five days. Taste masking could improve adherence, especially in pediatric patients, but flavoring or coating changes may affect dissolution, dose recovery, and regulatory comparability.

Potential approaches include:

• Flavored multiparticulates
• Polymer-coated granules
• Sweetener systems
• Ion-complexation technologies
• Granules designed for administration in yogurt, applesauce, or other soft foods

A taste-masked product could gain commercial value if it improves completion of the 20-dose regimen. The benefit must be balanced against added manufacturing cost and the need to demonstrate rapid release.

Dispersibility and administration flexibility

The label permits administration with soft food or liquid. A competitor could pursue granules with faster wetting, lower sedimentation, and more uniform dispersion. This may be useful in hospitals where administration speed is important.

The product should not require extensive preparation. A formulation that disperses quickly in a small volume and leaves minimal residue in the container could reduce dose loss and nursing time.

Pediatric usability

The pediatric dose is based on body-surface area and may be below the 10-gram adult packet strength. A lower-strength packet or calibrated multipart dose could address dose flexibility. This would create a lifecycle opportunity but could also increase packaging complexity and the risk of medication errors.

Possible product concepts include:

• 1-gram or 2-gram unit-dose packets
• Color-coded pediatric packets
• Premeasured dosing cups
• Multi-strength carton configurations
• Ready-to-disperse sachets

A pediatric presentation would require careful control of dose recovery and labeling clarity. It could also face a more complex regulatory pathway if it changes the reference product’s dosage form or administration characteristics.

What patents protect Vistogard and its formulation?

Vistogard is approved under FDA NDA 207232. The product’s principal legal protection is likely to arise from active-ingredient, method-of-use, formulation, and manufacturing claims rather than from the basic use of common excipients.[1]

For an abbreviated new drug application, the key legal questions are:

1. Which Vistogard patents are listed in the FDA Orange Book?
2. Which claims cover uridine triacetate for 5-fluorouracil or capecitabine toxicity?
3. Do any claims cover the specific granule composition or packet presentation?
4. Are the listed patents still unexpired?
5. Has any applicant submitted a Paragraph IV certification?
6. Are there settlements restricting launch timing?

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with NDA 207232.[2] A formulation that uses lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate does not automatically infringe a formulation patent. Infringement depends on the exact claim language, including ingredient ranges, particle characteristics, process limitations, and administration requirements.

Are there formulation-patent opportunities?

Yes. A follow-on developer could seek protection for:

• Moisture-stable uridine triacetate granules
• Taste-masked multiparticulates
• Specific particle-size distributions
• Low-residue dispersible granules
• Pediatric dose packets
• High-barrier packaging systems
• Manufacturing processes that improve content uniformity
• Formulations compatible with defined soft foods or liquids

The commercial strength of such patents would depend on whether the claimed feature produces a measurable advantage over the reference product. Broad claims covering routine use of standard excipients would face greater validity and obviousness risk than claims tied to demonstrated stability, dispersion, or dose-delivery performance.

When does Vistogard lose exclusivity?

Vistogard’s regulatory exclusivity and patent exclusivity are separate.

FDA approval in 2015 gave the product statutory periods of regulatory protection under the applicable new-drug framework. The Orange Book identifies the relevant exclusivity and patent information. Patent expiry may extend beyond regulatory exclusivity if valid listed patents remain in force.[2]

The practical generic-entry timeline depends on:

• The remaining term of listed patents
• Patent-term adjustment or extension
• The date of any generic application
• Paragraph IV litigation
• A 30-month stay of approval, where applicable
• Settlement terms
• The FDA’s determination of therapeutic equivalence and bioequivalence

Because Vistogard is an emergency-use product with a specialized granule presentation, a generic applicant may pursue a formulation that is compositionally different but pharmaceutically equivalent. Common excipient substitution alone does not establish a launch right. The applicant must address every applicable Orange Book patent through certification or a statement of non-infringement.

Are Paragraph IV challenges likely for Vistogard?

Paragraph IV risk is credible because uridine triacetate is a small-molecule active ingredient and the dosage form is an oral granule rather than a biologic delivery system. The main constraints are market size, emergency-use demand, and the need to support a product that hospitals may stock infrequently but must have available.

A Paragraph IV applicant would likely focus on:

• Method-of-use claims
• Granule composition claims
• Manufacturing-process claims
• Packet or dosage-form claims
• Non-infringement based on excipient substitution
• Invalidity based on obviousness or lack of written description

The commercial case for a challenge improves if the applicant can secure hospital contracts, oncology-distribution coverage, or preferred formulary placement before launch. The case weakens if expected volume is limited and patent litigation costs are high.

What FDA regulatory pathway would a Vistogard generic use?

A conventional generic would generally be evaluated under the abbreviated new drug application framework if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to Vistogard. The relevant comparison includes active ingredient, strength, dosage form, route of administration, and performance characteristics.[3]

Potential regulatory issues include:

• Demonstrating equivalent uridine triacetate exposure
• Establishing comparable dissolution or dispersion
• Showing equivalent packet dose delivery
• Addressing administration with soft food or liquid
• Supporting stability in the proposed package
• Evaluating inactive-ingredient safety, particularly lactose and pediatric use
• Matching labeling requirements

If a proposed product changes the dosage form, delivery mechanism, or clinical use materially, the regulatory pathway may become more complex than a standard ANDA. A 505(b)(2) strategy could be relevant for a differentiated formulation, but the pathway would depend on the nature of the change and the sponsor’s reliance on FDA findings for the reference product.

What commercial opportunities exist in Vistogard excipients?

The strongest opportunities are in formulation support and supply-chain execution rather than in commodity excipient sales alone.

Excipient suppliers

Suppliers can compete through:

• Low-moisture lactose grades
• Consistent particle-size microcrystalline cellulose
• High-purity colloidal silicon dioxide
• Lubricant grades optimized for low-dose incorporation
• Excipient combinations designed for direct blending
• Technical packages supporting regulatory qualification

For a high-dose powder product, flow performance and lot-to-lot consistency can matter more than nominal excipient price.

CDMOs and contract packagers

CDMOs can offer value through:

• Powder blending
• Granulation
• Unit-dose packet filling
• High-barrier packaging
• In-process weight control
• Stability studies
• Development of pediatric strengths
• Scale-up and technology transfer

Packet filling is a specialized capability. The supplier must control airborne powder, electrostatic effects, line clearance, and fill-weight variability while maintaining rapid production turnaround.

Lifecycle management

The most commercially defensible reformulations are likely to address a specific use problem:

• Easier pediatric dosing
• Improved palatability
• Faster preparation in emergency settings
• Reduced powder residue
• Longer shelf life under temperature and humidity stress
• Smaller or more portable emergency kits

A reformulation with no measurable administration or stability benefit would have limited pricing power.

How strong is the Vistogard patent estate?

The estate should be viewed as moderate from a formulation perspective and potentially stronger from a therapeutic-use perspective. The active ingredient is a defined small molecule, and the basic excipient system uses widely available pharmaceutical materials. That limits exclusivity based solely on common excipients.

Method-of-use protection can be commercially important because Vistogard’s value is tied to treatment of fluoropyrimidine toxicity within a narrow clinical window. A competitor that uses the same active ingredient for the same emergency indication may face greater patent exposure than one developing a materially different use or formulation.

The strongest follow-on protection would likely require:

• A clearly defined technical feature
• Comparative stability or dispersion data
• Evidence of improved dose delivery
• Narrow but defensible claim construction
• Commercial relevance in hospital and oncology settings

What generic launch scenarios exist?

Launch scenario	Commercial effect	Main risk
First-to-file Paragraph IV launch	Potential 180-day exclusivity and rapid market share capture	Patent litigation and limited market size
Authorized generic or license launch	Lower litigation risk and faster commercialization	Reduced margin and dependence on originator
Non-infringing formulation launch after patent expiry	Conventional generic competition	Price erosion and hospital contracting
Pediatric-strength launch	Differentiated positioning	Regulatory and manufacturing complexity
Taste-masked or dispersible product	Potential premium pricing	Bioequivalence and development risk
Hospital emergency-kit contract	Stable institutional demand	Low utilization and inventory-management pressure

An early generic launch would probably create a concentrated market rather than a large-volume retail generic market. Vistogard is used in a narrow emergency setting, and stocking decisions are driven by clinical readiness, distributor availability, and reimbursement.

What is the revenue exposure for Vistogard?

Publicly cited sources do not provide a reliable, product-level revenue figure in the materials reviewed. Revenue exposure should therefore be assessed through market structure rather than unsupported sales estimates.

Relevant commercial variables include:

• Number of fluoropyrimidine-treated patients
• Incidence of severe toxicity and overdose
• Hospital stocking requirements
• Reimbursement and payer coverage
• Use of capecitabine in outpatient oncology
• Product wastage from shelf-life expiration
• Emergency-distribution margins
• Generic price competition

The product has a high value per treated event because it can prevent or reduce severe toxicity, but the number of treated events is much smaller than the number of patients receiving fluorouracil or capecitabine. This produces a specialized, high-consequence market with limited volume.

What geographic coverage and manufacturing barriers matter?

The commercial opportunity is strongest in markets with:

• High fluoropyrimidine utilization
• Established oncology emergency protocols
• Hospital pharmacy stocking systems
• Reimbursement for antidote products
• Local regulatory recognition of uridine triacetate

Manufacturing barriers are manageable but not trivial. They include active-ingredient sourcing, powder processing, packet-filling capacity, high-barrier packaging, and quality systems for a product used in time-sensitive emergencies.

Supply interruption risk may be more commercially damaging than ordinary generic substitution because hospitals must maintain availability even when utilization is low. A supplier with reliable inventory, dual-source raw materials, and validated packaging capacity could compete effectively without offering the lowest unit price.

Key Takeaways

• Vistogard contains 10 grams of uridine triacetate in oral granules per packet.
• Its inactive ingredients are lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
• The core formulation opportunity is improved powder flow, moisture stability, dispersion, palatability, and pediatric dosing.
• Common excipients provide limited standalone patent differentiation.
• Method-of-use patents may be more commercially significant than basic excipient claims.
• Generic developers must address Orange Book patents, pharmaceutical equivalence, bioequivalence, packet delivery, and administration with food or liquid.
• The market is specialized and emergency-driven, with potentially high value per treated event but limited total volume.
• CDMOs, excipient suppliers, packet-fillers, and developers of pediatric or taste-masked formulations have the clearest commercial opportunities.

FAQs About Vistogard Excipient and Commercial Strategy

Can lactose-free Vistogard be developed?

A lactose-free product is technically feasible using alternative diluents, but it would need to demonstrate equivalent performance, stability, dose delivery, and bioequivalence. The commercial value would depend on the prevalence of clinically meaningful lactose intolerance among intended users.

Could Vistogard be supplied as a tablet?

A tablet would require a different dosage-form strategy because the standard dose is 10 grams. A tablet presentation would likely be impractical unless developed as a multipart tablet, dispersible system, or high-load formulation. It may also create new bioequivalence and administration requirements.

Is uridine triacetate used in another FDA-approved product?

Yes. Uridine triacetate is also the active ingredient in Xuriden, which is approved for hereditary orotic aciduria. The two products have different indications, dosing contexts, and commercial positioning.[4]

Could a competitor use different excipients and still obtain approval?

Yes. A generic applicant may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, safety, quality, and labeling requirements. Different excipients do not by themselves avoid patent infringement.

What is the main formulation risk for a Vistogard follow-on product?

The main risk is failure to maintain consistent packet dosing and rapid, complete dispersion after storage. Moisture uptake, powder segregation, caking, and residue can affect both manufacturing performance and patient administration.

References

1. U.S. Food and Drug Administration. (2023). Vistogard (uridine triacetate) oral granules prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2023). Xuriden (uridine triacetate) prescribing information. FDA/DailyMed.